Epi Biotech Co Ltd

Epi Biotech Co Ltd exhibits a distressed capital structure characterized by negative total equity of -11,903,878,350 KRW and total liabilities of 17,201,455,210 KRW, which exceed total assets of 5,297,576,860 KRW. The company holds 708,529,400 KRW in cash and equivalents against long-term debt of 9,957,396,890 KRW, resulting in a negative net cash position. Liquidity is constrained, evidenced by a current ratio of 0.18, indicating that current liabilities significantly outweigh current assets. The debt-to-equity ratio is reported as -0.84, a mathematical artifact of the negative equity base, highlighting the insolvency risk inherent in the balance sheet.

Profitability metrics reflect the company's pre-profit or early-stage biotechnology profile, with a net income of -1,909,732,700 KRW and an operating income of -2,076,205,380 KRW. Despite the losses, the company maintains a high gross profit margin, with gross profit of 1,682,973,400 KRW against revenue of 1,928,755,900 KRW, suggesting that core product or service delivery is marginally profitable before overhead and R&D expenses. Return on assets is -0.3605, indicating inefficient asset utilization in generating earnings, while return on equity is reported as 0.1604, though this metric is distorted by the negative equity denominator and should be interpreted with caution.

Revenue generation is limited in absolute terms, with total revenue of 1,928,755,900 KRW for the latest period. The input data does not provide a breakdown of revenue by segment or geography, preventing an analysis of concentration risk or regional exposure. The company's activity is broadly classified as biotechnology, implying that revenue may stem from licensing, collaborations, or early-stage product sales, but specific customer or product mix details are absent from the available financial snapshot.

Growth trajectory analysis is hindered by the absence of historical period data in the input, preventing a year-over-year or quarter-over-quarter comparison of revenue and net income trends. Without historical context, it is not possible to determine if the current revenue level represents expansion, contraction, or stability relative to prior periods. The single-period snapshot shows a negative free cash flow of -1,491,901,540 KRW, driven by negative operating cash flow of -662,883,740 KRW and capital expenditures of -101,683,840 KRW, indicating ongoing cash burn.

Risk assessment identifies medium liquidity risk and low dilution risk, with a key flag noting that net cash is negative after subtracting total debt. The negative equity position poses a significant solvency risk, requiring either substantial debt restructuring, equity infusion, or rapid revenue growth to stabilize the balance sheet. The low dilution risk suggests that there are no immediate plans for significant share issuance, as basic and diluted shares outstanding are identical at 2,306,879 shares.

Recent events, filing observations, and news transcripts are not provided in the input data, limiting the ability to assess recent corporate actions or market sentiment shifts. The analysis relies solely on the static financial snapshot and classification data, which highlight the structural financial challenges faced by the company.

Net losses narrowed substantially to 1.91 billion KRW from 4.88 billion KRW, indicating improved cost efficiency.

Free cash flow improved significantly to -1.49 billion KRW from -4.28 billion KRW, reducing cash burn rate.

Gross profit expanded to 1.68 billion KRW, up from 589 million KRW, reflecting better product margins.

Operating income loss decreased to 2.08 billion KRW from 2.33 billion KRW, showing operational stabilization.

The company carries a high credit risk flag, signaling potential difficulties in meeting financial obligations.

Book value is negative at -11.9 billion KRW, indicating accumulated losses exceed total assets.

Cash conversion ratio sits at 0.35, placing the company in the bottom quartile of its cohort.